Sugi Predict

Sugi Predict / Compounds / Tyrosine

Tyrosine

Tyrosine

SCHEMBL606713

N[C@@H](Cc1c[nH]cn1)C(=O)O.N[C@@H](Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 3/20 0.65
▸ PTGS1 P23219 3/20 0.47
▸ ALPI P09923 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ XIAP P98170 1/20 0.47
▸ HSD17B10 Q99714 3/20 0.46
▸ ALOX15 P16050 3/20 0.46
▸ HIF1A Q16665 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ ADORA3 P0DMS8 2/20 0.46
▸ HTR2A P28223 2/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ USP2 O75604 1/20 0.46
▸ EGFR P00533 1/20 0.46
▸ LCK P06239 1/20 0.46
▸ FYN P06241 1/20 0.46
▸ PTGS2 P35354 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ GRIA2 P42262 1/20 0.44
▸ TPH1 P17752 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tyrosine SCHEMBL8315968 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL28433898 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL606712 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL8316690 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL25286397 0.96 SLC7A5 (0.60) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL27792454 0.94 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL8904139 0.92 SLC7A5 (0.55) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL28519346 0.92 SLC7A5 (0.55) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL9978769 0.90 SLC7A5 (0.52) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL18297990 0.90 SLC7A5 (0.52) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3430383-B1 CA IX-TARGET NIR DYES AND THEIR USES ON TARGET LABORATORIES LLC (US) 2024-06-26 — — EP claimed
US-11555821-B2 CA IX-NIR dyes and their uses On Target Laboratories, Inc. (US) 2023-01-17 — — US claimed
US-11484607-B2 PSMA-targeted NIR dyes and their uses On Target Laboratories, LLC (US) 2022-11-01 — — US claimed
US-20210063406-A1 CA IX - NIR DYES AND THEIR USES On Target Laboratories, Inc. 2021-03-04 — — US claimed
US-20210046194-A1 PSMA-TARGETED NIR DYES AND THEIR USES On Target Laboratories, Inc. 2021-02-18 — — US claimed
US-10557854-B2 CA IX—NIR dyes and their uses On Target Laboratories, LLC (US) 2020-02-11 — — US claimed
EP-3544992-A1 G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS The Regents of The University of California (US) 2019-10-02 — — EP claimed
CN-109791107-A Target the NIR dyestuff and application thereof of CA IX 目标实验室有限责任公司 2019-05-21 — — CN claimed
EP-3430383-A1 CA IX-TARGET NIR DYES AND THEIR USES On Target Laboratories, LLC (US) 2019-01-23 — — EP claimed
CN-108464448-A Nitrite-free curing agent, without nitre ham and preparation method thereof 浙江省农业科学院 2018-08-31 — — CN claimed
EP-1390074-A4 NOVEL COMPOSITIONS AND USES THEREFOR UNIV QUEENSLAND (AU) 2007-03-14 — — EP claimed
US-20070004622-A1 Imidazole derivative, process for producing the same, and use REGEN BIOTECH, INC. (KR) 2007-01-04 — — US claimed
EP-1292615-B1 MODIFIED MORBILLIVIRUS V PROTEINS WYETH CORP (US) 2006-10-25 — — EP claimed
EP-1620122-A1 USE OF A PEPTIDE THAT INTERACTS WITH ALPHA V BETA3 INTEGRIN OF ENDOTHELIAL CELL Regen Biotech Inc. (KR) 2006-02-01 — — EP claimed
US-20040241177-A1 For producing antigen-primed antigen-presenting cells for eliciting a humoral and cellular immunity against target antigens; intracellular proteolytic degradation of second antigen is increased; immunogens; sustained release UNIQUEST PTY LTD (AU) 2004-12-02 — — US claimed
WO-2004087193-A1 USE OF A PEPTIDE THAT INTERACTS WITH ALPHA V BETA3 INTEGRIN OF ENDOTHELIAL CELL REGEN BIOTECH INC.. (KR) 2004-10-14 — — WO claimed
EP-1390074-A1 NOVEL COMPOSITIONS AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2004-02-25 — — EP claimed
US-6664066-B2 Mutant measles virus V protein; gene expression and engineering WYETH HOLDINGS CORPORATION 2003-12-16 — — US claimed
US-20030206925-A1 MODIFIED MORBILLIVIRUS V PROTEINS WYETH HOLDINGS CORPORATION 2003-11-06 — — US claimed
WO-2002083181-A1 NOVEL COMPOSITIONS AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2002-10-24 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210046194-A1 PSMA-TARGETED NIR DYES AND THEIR USES KLK3, FOLH1, CD47 SLC7A5 854/4885PTGS1 1110/4885ALPI 447/4885
US-11555821-B2 CA IX-NIR dyes and their uses CA9, CA13, CA4 SLC7A5 171/4885PTGS1 1810/4885ALPI 67/4885
US-11484607-B2 PSMA-targeted NIR dyes and their uses KLK3, FOLH1, CD47 SLC7A5 854/4885PTGS1 1110/4885ALPI 447/4885
US-10557854-B2 CA IX—NIR dyes and their uses CA9, CA13, CA4 SLC7A5 157/4885PTGS1 1708/4885ALPI 95/4885
US-20210063406-A1 CA IX - NIR DYES AND THEIR USES CA9, CA13, CA4 SLC7A5 171/4885PTGS1 1810/4885ALPI 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.